A multicentre, prospective study analysing real-world effectiveness of cardiovascular and metabolic treatments routinely used in Canadian clinical practice
Latest Information Update: 02 Feb 2021
Price :
$35 *
At a glance
- Drugs Azilsartan medoxomil (Primary) ; Colesevelam (Primary) ; Diltiazem (Primary) ; Metformin (Primary)
- Indications Essential hypertension; Hypercholesterolaemia; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms CV-CARE
- Sponsors Bausch Health Companies
- 02 Feb 2021 New trial record